Chris Appleby joined Sciensus in 2011 as a Cancer Pharmacist, following four years in the NHS. He led the Cancer Pharmacy, overseeing compounding and clinical trials, before serving as Chief Pharmacist for six years. During this time, he helped establish our Medical Advisory Committee and led the construction of our aseptic compounding unit.
In 2022, Chris became Business Development Director – Specialist Services, focusing on new propositions such as clinical trials and direct-to-hospital compounding. His initiatives include developing Sciensus’ commercial compounding services, collaborating with hospitals and expanding our portfolio. Chris has also completed an MBA and continues to drive growth in cancer care and specialised patient pathways.